

Robert Knobler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5927479/publications.pdf>

Version: 2024-02-01

78
papers

11,220
citations

81839

39
h-index

69214

77
g-index

220
all docs

220
docs citations

220
times ranked

6229
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. <i>Blood</i> , 2022, 140, 419-437.	0.6	58
2	Extracorporeal Photopheresis With Low-Dose Immunosuppression in High-Risk Heart Transplant Patientsâ€”A Pilot Study. <i>Transplant International</i> , 2022, 35, 10320.	0.8	6
3	Treatment of earlyâ€”stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPi) study*. <i>British Journal of Dermatology</i> , 2021, 184, 722-730.	1.4	39
4	Should we be imaging lymph nodes at initial diagnosis of earlyâ€”stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPi) international study*. <i>British Journal of Dermatology</i> , 2021, 184, 524-531.	1.4	18
5	European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 â€” Part 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 27-49.	1.3	28
6	Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIbâ€”IVB mycosis fungoides/SÃ©zary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT). <i>European Journal of Cancer</i> , 2021, 156, S22-S23.	1.3	3
7	Characteristics associated with significantly worse quality of life in mycosis fungoides/SÃ©zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index () Tj ETQq1 1 0.784314 rgBT1@verlock710 Tf 504		
8	Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010â€”2015. <i>Journal of Dermatological Treatment</i> , 2020, 31, 91-98.	1.1	7
9	European dermatology forum â€” updated guidelines on the use of extracorporeal photopheresis 2020 â€” part 1. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2693-2716.	1.3	49
10	Management of primary cutaneous lymphoma patients during COVIDâ€”19 pandemic: EORTC CLTF guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1633-1636.	1.3	14
11	Outcome of Extracorporeal Photopheresis as an Add-On Therapy for Antibody-Mediated Rejection in Lung Transplant Recipients. <i>Transfusion Medicine and Hemotherapy</i> , 2020, 47, 205-213.	0.7	11
12	Recent advances in understanding and managing cutaneous T-cell lymphomas. <i>F1000Research</i> , 2020, 9, 331.	0.8	18
13	Cutaneous manifestations of acute and chronic graft-versus-host disease. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 76-87.	0.8	5
14	A potassium-titanyl-phosphate laser is an efficacious tool in the treatment of pyogenic granulomas. A retrospective study in 28 patients. <i>Photochemical and Photobiological Sciences</i> , 2019, 18, 343-348.	1.6	4
15	Effects of extracorporeal photopheresis on serum levels of vitamin D: Preliminary Data from a Pilot Study. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2019, 35, 51-53.	0.7	1
16	The PROCLIPi international registry of earlyâ€”stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.4	127
17	Blood classification and blood response criteria in mycosis fungoides and SÃ©zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. <i>European Journal of Cancer</i> , 2018, 93, 47-56.	1.3	105
18	Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 33-50.	3.3	112

#	ARTICLE	IF	CITATIONS
19	Molecular classification of tumour cells in a patient with intravascular large B-cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 178, 215-221.	1.4	14
20	Extracorporeal Photopheresis—An Overview. <i>Frontiers in Medicine</i> , 2018, 5, 236.	1.2	72
21	Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. <i>European Journal of Cancer</i> , 2018, 101, 278-280.	1.3	10
22	Patients' Illness Perception as a Tool to Improve Individual Disease Management in Primary Cutaneous Lymphomas. <i>Acta Dermato-Venereologica</i> , 2018, 98, 240-245.	0.6	20
23	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome – Update 2017. <i>European Journal of Cancer</i> , 2017, 77, 57-74.	1.3	363
24	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. <i>European Journal of Dermatology</i> , 2017, 27, 286-294.	0.3	16
25	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. <i>Annals of Oncology</i> , 2017, 28, 2517-2525.	0.6	98
26	European dermatology forum S1 guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1581-1594.	1.3	79
27	European Dermatology Forum S1 guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1401-1424.	1.3	148
28	Histopathological and immunophenotypical criteria for the diagnosis of Sezary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 9. <i>British Journal of Dermatology</i> , 2015, 173, 93-105.	1.4	67
29	Aggressive epidermotropic cutaneous CD8 ⁺ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. <i>Histopathology</i> , 2015, 67, 425-441.	1.6	86
30	Epidermal Elafin Expression Is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2015, 135, 999-1006.	0.3	30
31	Incidence of lung cancer in patients with systemic sclerosis treated with extracorporeal photopheresis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2015, 31, 175-183.	0.7	7
32	Nitrogen mustard revisited. <i>British Journal of Dermatology</i> , 2014, 170, 495-495.	1.4	5
33	Guidelines on the use of extracorporeal photopheresis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1-37.	1.3	212
34	ECP and solid organ transplantation. <i>Transfusion and Apheresis Science</i> , 2014, 50, 358-362.	0.5	15
35	Extracorporeal photopheresis in acute and chronic graft-versus-host disease. <i>Transfusion and Apheresis Science</i> , 2014, 50, 349-357.	0.5	44
36	Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. <i>Haematologica</i> , 2014, 99, 1746-1752.	1.7	27

#	ARTICLE	IF	CITATIONS
37	Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. <i>Blood</i> , 2014, 123, 290-299.	0.6	108
38	Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 293-300.	0.9	41
39	New developments in acute graft-versus-host disease. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 98-101.	0.3	0
40	Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1129-1133.	2.0	83
41	Photopheresis (extracorporeal photochemotherapy). <i>Photochemical and Photobiological Sciences</i> , 2013, 12, 22-28.	1.6	31
42	Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature. <i>International Journal of Dermatology</i> , 2013, 52, 1308-1318.	0.5	35
43	Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. <i>Leukemia</i> , 2012, 26, 746-756.	3.3	97
44	Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2012, 28, 250-257.	0.7	41
45	A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 950-957.	0.3	114
46	Progressive Improvement in Cutaneous and Extracutaneous Chronic Graft-versus-Host Disease after a 24-Week Course of Extracorporeal Photopheresis—Results of a Crossover Randomized Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1775-1782.	2.0	127
47	Tratamiento de linfomas cutáneos de células T con fotoinmunoterapia extracorporea (Fotoféresis). <i>Piel</i> , 2011, 26, 523-531.	0.0	0
48	Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	0.8	550
49	Trafficking of 8-MOP Treated Leucocytes After Extracorporeal Photopheresis in Humans. <i>Blood</i> , 2011, 118, 1258-1258.	0.6	1
50	Photoepilation with variable pulsed light in non-facial body areas: evaluation of efficacy and safety. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 518-523.	1.3	8
51	Role of Extracorporeal Photopheresis (ECP) in Treatment of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1747-1748.	2.0	39
52	EORTC 21012: Phase II Multicentre Study of Caelyx, a Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, IVa and IVb with or without Previous Chemotherapy. <i>Blood</i> , 2010, 116, 2823-2823.	0.6	1
53	The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform. <i>Blood</i> , 2010, 116, 4896-4896.	0.6	0
54	Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 829-836.	0.9	39

#	ARTICLE	IF	CITATIONS
55	Extracorporeal photopheresis: Past, present, and future. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 652-665.	0.6	116
56	Assessment of the Potential of Immature CD19+CD21- B-Lymphocytes to Predict Response to Various Systemic Therapies in Chronic Graft-Versus-Host Disease.. <i>Blood</i> , 2009, 114, 2226-2226.	0.6	0
57	Evaluation of safety and efficacy of variable pulsed light in the treatment of unwanted hair in 77 volunteers. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 311-315.	1.3	19
58	A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. <i>Blood</i> , 2008, 112, 2667-2674.	0.6	320
59	Monitoring of B Cell Subpopulations in Patients with Chronic Graft-Versus-Host Disease May Predict Response to Extracorporeal Photopheresis. <i>Blood</i> , 2008, 112, 467-467.	0.6	0
60	Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what?. <i>European Journal of Cancer</i> , 2007, 43, 2321-2329.	1.3	56
61	Revisions to the staging and classification of mycosis fungoides and SÅ©zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 1713-1722.	0.6	1,243
62	Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.. <i>Blood</i> , 2007, 110, 2561-2561.	0.6	12
63	EORTC consensus recommendations for the treatment of mycosis fungoides/SÅ©zary syndrome. <i>European Journal of Cancer</i> , 2006, 42, 1014-1030.	1.3	390
64	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 252-266.	2.0	445
65	WHO-EORTC classification for cutaneous lymphomas. <i>Blood</i> , 2005, 105, 3768-3785.	0.6	3,529
66	Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. <i>Transfusion and Apheresis Science</i> , 2003, 28, 81-89.	0.5	57
67	Extracorporeal photochemotherapy in patients with steroid-dependent Crohnâ€™s disease: a prospective pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1313-1322.	1.9	61
68	Extracorporeal Photochemoimmunotherapy in Cutaneous T Cell Lymphomas. <i>Annals of the New York Academy of Sciences</i> , 2001, 941, 123-138.	1.8	42
69	Extracorporeal photochemotherapy--present and future. <i>Vox Sanguinis</i> , 2000, 78 Suppl 2, 197-201.	0.7	8
70	Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. <i>British Journal of Rheumatology</i> , 1997, 36, 1276-1282.	2.5	47
71	Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA. <i>Archives of Dermatological Research</i> , 1996, 288, 691-696.	1.1	6
72	Multiplex PCR for rapid detection of Tâ€cell receptorâ€gamma chain gene rearrangements in patients with lymphoproliferative diseases. <i>British Journal of Haematology</i> , 1996, 94, 136-139.	1.2	40

#	ARTICLE	IF	CITATIONS
73	Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA. Archives of Dermatological Research, 1996, 288, 691-696.	1.1	3
74	Photopheresis and the Red Man Syndrome. Dermatology, 1995, 190, 97-98.	0.9	9
75	CYTOKINE RELEASE BY PERIPHERAL BLOOD MONONUCLEAR CELLS IS AFFECTED BY 8-METHOXYPORALEN PLUS UV-A. Photochemistry and Photobiology, 1994, 59, 182-188.	1.3	48
76	Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. Journal of the American Academy of Dermatology, 1992, 27, 427-433.	0.6	238
77	Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy. New England Journal of Medicine, 1987, 316, 297-303.	13.9	1,192
78	Sex steroid hormone receptor analysis in malignant melanoma. British Journal of Dermatology, 1982, 107, 54-59.	1.4	18